Zidovudine

Generic Name: Zidovudine

Brand Names: Combivir, Retrovir, Trizivir

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃N_₅O_₄

CAS Number: 30516-87-1

Unique Ingredient Identifier: 4B9XT59T7S

Background: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]

Indication: Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.

Associated Conditions: HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Phase 2

Completed

Conditions: HIV-1

Interventions: Drug: Rilpivirine
Drug: Zidovudine
Drug: Abacavir
Drug: Tenofovir disoproxil fumarate
Drug: Lamivudine
Drug: Emtricitabine

First Posted Date: 2008-12-01

Last Posted Date: 2024-06-25

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 54

Registration Number: NCT00799864

Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART

Early Phase 1

Completed

Conditions: Malaria
HIV Infections

Interventions: Drug: Lamivudine
Drug: Lopinavir/Ritonavir
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2008-07-21

Last Posted Date: 2016-09-19

Lead Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Target Recruit Count: 105

Registration Number: NCT00719602

Locations: 🇿🇲
George Clinic CRS (30273), Lusaka, Zambia
🇺🇬
Makerere University - JHU Research Collaboration (30293), Kampala, Uganda
🇲🇼
University of North Carolina Lilongwe (12001), Lilongwe, Malawi

Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GPO-Vir Z30 tablet
Drug: Lamivudine
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2008-05-06

Last Posted Date: 2021-11-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT00672412

Locations: 🇹🇭
Prapokklao Hosp. CRS, Muang District, Chantaburi, Thailand
🇹🇭
Siriraj Hospital Mahidol University CRS, Bangkok, Ratchathewi, Thailand
🇹🇭
Chonburi Hosp. CRS, Chonburi, Thailand

and more 1 locations

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Drug: Lopinavir/ritonavir
Drug: Emtricitabine/Tenofovir disoproxil fumarate
Drug: Tenofovir disoproxil fumarate
Drug: Zidovudine
Drug: Emtricitabine

First Posted Date: 2008-02-06

Last Posted Date: 2018-10-12

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 529

Registration Number: NCT00608569

Locations: 🇺🇬
JCRC CRS, Kampala, Uganda
🇭🇹
Les Centres GHESKIO CRS, Bicentenaire, Port-au-Prince, Haiti
🇵🇪
Barranco CRS, Lima, Peru

and more 6 locations

Bioequivalency Study of Zidovudine Under Fasting Conditions

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2008-01-28

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 52

Registration Number: NCT00602550

Locations: 🇺🇸
CEDRA Clinical Research, Austin, Texas, United States

Bioequivalency Study of Zidovudine Under Fed Conditions

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2008-01-28

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 52

Registration Number: NCT00601562

Locations: 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir DF
Drug: Zidovudine
Drug: Stavudine

First Posted Date: 2007-09-14

Last Posted Date: 2018-03-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 97

Registration Number: NCT00528957

Locations: 🇵🇦
Hospital del Nino, Panama City, Panama
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Children's Diagnostic and Treatment Center, Inc, Fort Lauderdale, Florida, United States

and more 6 locations

Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2007-02-06

Last Posted Date: 2007-05-11

Lead Sponsor: RFS Pharma, LLC

Target Recruit Count: 24

Registration Number: NCT00432016

Locations: 🇦🇷
Hospital Privado Modelo, Buenos Aires, Argentina

Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand

Phase 3

Terminated

Conditions: HIV Infections
Pregnancy

Interventions: Drug: Maternal lopinavir+ritonavir
Drug: Maternal placebo and infant nevirapine
Drug: Maternal and infant nevirapine
Drug: zidovudine

First Posted Date: 2006-12-11

Last Posted Date: 2016-01-28

Lead Sponsor: Institut de Recherche pour le Developpement

Target Recruit Count: 435

Registration Number: NCT00409591

Locations: 🇹🇭
Bhumibol Adulyadej Hospital, Saimai, Bangkok, Thailand
🇹🇭
Nopparat Rajathanee Hospital, Kannayao, Bangkok, Thailand
🇹🇭
Banglamung Hospital, Banglamung, Chonburi, Thailand

and more 40 locations

Antiretroviral Therapy for Advanced HIV Disease in South Africa

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Zidovudine
Drug: Stavudine
Drug: Lamivudine
Drug: Didanosine
Drug: Lopinavir/Ritonavir
Drug: Efavirenz

First Posted Date: 2006-06-21

Last Posted Date: 2013-05-21

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 1771

Registration Number: NCT00342355

Locations: 🇿🇦
Mtubatuba SIckbay, Kwazulu-Natal, South Africa
🇿🇦
Umtata Sickbay, Eastaern Cape, South Africa
🇿🇦
South African Military Health Services (SAMHS), Centurion, South Africa

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy